Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Significance: Protein-based drugs are very active in treating cancer, but their efficacy is limited by the formation of neutralizing antidrug antibodies (ADAs). Recombinant immunotoxins are proteins that are very effective in patients with leukemia, in whom immunity is suppressed, but induce ADAs, which compromise their activity, in patients with intact immunity. Here we used an immunomodulator that is encapsulated in a nanoparticle delivery system (SVP-R) to induce specific immune tolerance to immunotoxins in mice. SVP-R induces immune tolerance, prevents ADA formation, and prevents the drug neutralization and clearance that results in restoration of its antitumor activity. Importantly, the combination is also efficacious in mice with preexisting antibodies, indicating that this approach can benefit patients who often have such antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · cited 1×
“The anti–CTLA-4 mAb used in our study has been studied for anticancer activity in CT26 and MC38 (mouse colon carcinoma) tumor models (42), and it is thought to act by reducing Treg cells and concomitantly activating effector T cells at the tumor site (42).”
MethodPolymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
Maldonado, R. A., LaMothe, R. A., Ferrari, J. D., Zhang, A.-H., Rossi, R. J., Kolte, P. N., Griset, A. P., O’Neil, C., Altreuter, D. H., Browning, E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408686111 · Cited by 441 · cited 2×
“Unlike general immune suppressive therapies, SVP-R has a strong affinity to accumulate in the lymph nodes and spleen (21), where it is selectively endocytosed by antigen-presenting cells (Fig.”
BackgroundSelf-citationImmunogenicity of protein therapeutics: The key causes, consequences and challenges
Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372 · cited 1×
“Repeated administration of immunogenic anticancer drugs, such as chimeric antigen receptor T cells (1), enzyme therapy (2), monoclonal antibodies (mAbs) (3), antibody drug conjugates (ADCs), recombinant immunotoxins (4) and viral-based gene therapy vectors (5), lead to the formation of antidrug antibodies (ADAs), resu…”
BackgroundRapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Zhang, A.-H., Rossi, R. J., Yoon, J., Wang, H., & Scott, D. W. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2015.11.004 · Cited by 65
Effective depletion of pre-existing anti-AAV antibodies requires broad immune targeting
Velazquez, V. M., Meadows, A. S., Pineda, R. J., Camboni, M., McCarty, D. M., & Fu, H. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.01.003 · Cited by 43
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Self-citationEvaluating and mitigating the immunogenicity of therapeutic proteins
Sauna, Z. E., Lagassé, D., Pedras-Vasconcelos, J., Golding, B., & Rosenberg, A. S. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.05.008 · Cited by 118
Sands, E., Kivitz, A., DeHaan, W., Leung, S. S., Johnston, L., & Kishimoto, T. K. (2022) · Nature Communications · doi:10.1038/s41467-021-27945-7 · Cited by 61
Self-citationIlyinskii, P. O., Michaud, A. M., Roy, C. J., Rizzo, G. L., Elkins, S. L., Capela, T., Chowdhury, A. C., Leung, S. S., & Kishimoto, T. K. (2021) · Science Advances · doi:10.1126/sciadv.abd0321 · Cited by 56
“2 of 13 transgene, human factor IX, could only be detected when the immune response to the first vector dose was inhibited by co-administration of ImmTOR (20).”
BackgroundSelf-citation
Metadata
- Authors
- Mazor, R., King, E. M., Onda, M., Cuburu, N., Addissie, S., Crown, D., Liu, X.-F., Kishimoto, T. K., & Pastan, I.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-01-08
- Volume
- 115
- Issue
- 4
- Pages
- E733-E742
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2784147308
- Cited by
- 49
- References
- 7
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. https://app.cochat.ai/papers/10.1073/pnas.1717063115
- The paper
- Mazor, R., King, E. M., Onda, M., Cuburu, N., Addissie, S., Crown, D., Liu, X.-F., Kishimoto, T. K., & Pastan, I. (2018). Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1717063115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.